Integrating paroxysmal nocturnal hemoglobinuria (PNH) into mainstream hematological curriculum training
Abstract
Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra ‐ orphan life ‐ threatening disorder characterized by chronic intravascular hemolysis (IVH) and thrombosis. 1 Prior to eculizumab approval, patients with PNH had a median survival of between 10 and 22 years 2,3 with thrombosis accounting for 22% – 67% of death in case series and 29% – 44% of patients having at least one event. 2,4 Since the introduction of complement inhibitors, life expectancy in countries where treatment is available has nearly normalized. 5 As symptoms of PNH can vary and are often non ‐ specific, patients can present to a variety of medical specialties, leading to delays in diagnosis and appropriate treatment. Here, we address issues around underdiagnosis and mis-diagnosis of PNH and provide an evidence ‐ based overview of current educational gaps and diagnostic challenges facing hema-tologists. We describe in more detail what the education, and ultimately the knowledge for clinical practice about PNH, of a trainee in hematology should include. This is an activity of the Gaucher Disease/Rare Disease Task Force, an independent Sub ‐ Committee of the Granulocytes and Constitutional Marrow Failure Syndromes' Scientific Working Group of EHA, and the description which follows will be submitted for approval by the EHA Curriculum ‐ Exam Committee.